Free Oncology CME

  • FREE

    ScientiaCME Hematology/Oncology

    Target Audience: Hematologists

    See full details chevron_right
    • Cost: Free
    • Credit hours: 7.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    ScientiaCME Advances in the management of acute lymphoblastic leukemia (ALL) in children and adolescents

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Acute lymphoblastic leukemia (ALL) is one of a group of malignancies marked by unregulated growth of immature lymphoid cells. Each year, over 6,500 new cases are diagnosed, and ALL claims an estimated 1,390 lives in the same timeframe. The incidence of ALL peaks at 1 to 4 years of age, and it accounts for three quarters of cases of acute leukemia in children. The signs and symptoms of ALL are nonspecific and can include fatigue, malaise, or palpitations associated with anemia; fever with or without infection due to leukopenia or leukocytosis; petechiae; and bleeding or bruising of the oral mucosa or skin. Although the precise etiology of ALL remains unknown, some cases have been associated with exposure to ionizing, toxic chemicals, and herbicides; genetic conditions such as Down syndrome, Fanconi syndrome, neurofibromatosis; and viruses like human T-lymphotropic viruses 1 and 2 and Epstein-Barr virus.

    Target Audience:
    HCPs including: pediatric hematology-oncology, hematology, oncology, pathology, and those who otherwise commonly care for or clinically encounter patients with ALL.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 23, 2023
    • Expiration of CME credit: September 23, 2024
  • FREE

    ScientiaCME Challenges and updates in the management of von Hippel-Lindau disease and related tumors

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Von Hippel-Lindau (VHL) disease is a rare genetic condition caused by an autosomal dominant mutation of the VHL tumor suppressor gene. The mutation gives rise to an abnormal VHL protein that cannot bind effectively to protein HIF-1α, leading to the transcription of multiple genes and upregulation of growth factors. The condition is thought to affect between 1 in 39,000 and 1 in 91,000, with a birth incidence of between 1 in 36,000 and 1 in 45,500. Diagnosis of VHL disease is established when the patient undergoes genetic testing and a pathogenic mutation of the VHL gene is found. Genetic testing is typically conducted if the patient has a family history of VHL or they are showing signs of VHL-related symptoms. VHL disease is characterized by tumors and cysts growing in various parts of the body, including the brain, spine, eyes, inner ears, pancreas, kidneys, adrenal glands, and reproductive tract. The clinical presentation of the disease is different in every patient and is impossible to predict, so close monitoring is required. Complications of the disease are on a case-by-case basis, but patients with VHL are at an increased risk of developing some cancers, particularly clear cell renal cell carcinoma (RCC) and pancreatic cancer.

    Target Audience:
    HCPs including: Medical and genitourinary oncologists, urologists, and nephrologists; physician assistants, nurse practitioners, and pharmacists specializing in the aforementioned areas of specialty; and any other HCPs involved or interested in treatment of VHL disease.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 08, 2023
    • Expiration of CME credit: September 08, 2024
  • FREE

    ScientiaCME Advanced systemic mastocytosis: from recognition to treatment

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Systemic mastocytosis (SM) is a heterogeneous group of disorders caused by proliferation of abnormal clonal mastocytes, which accumulate in the skin and/or other organ systems. Mastocytosis, including SM, was reclassified as a distinct disease subtype in 2016, when the World Health Organization (WHO) removed mastocytosis from the myeloproliferative neoplasm (MPN) group. The WHO defines 5 SM subtypes, ranging from indolent SM, which is associated with mild symptoms and near-normal life expectancy, to mast cell leukemia, which is an aggressive hematologic malignancy associated with median survival of less than 1 year.

    Target Audience:
    HCPs including: hematology/oncology specialists, allergists, and clinical immunologists, dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in those areas of specialty; and any other healthcare professionals with an interest in or who may clinically encounter patients with systemic mastocytosis.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 28, 2023
    • Expiration of CME credit: September 28, 2025
  • FREE

    ScientiaCME Best practice in the systemic treatment of advanced and recurrent endometrial cancer

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Endometrial cancer is the most common gynecologic cancer and the fourth most common cancer in women living in the United States, with approximately 66,000 cancers of the uterine corpus diagnosed every year and over 12,000 associated deaths. The vast majority of women are diagnosed with endometrial cancer after the age of 50, and risk factors are obesity, level of physical activity, increasing age, and the presence of a variety of comorbid, chronic health conditions. The costs associated with endometrial cancer may amount to tens of thousands of dollars per patient, depending on the stage of disease upon diagnosis. The five-year survival rate for patients with localized disease is 95%, but survival rates drop to 18% in patients with advanced disease, one in ten patients is diagnosed with distant cancer, representing an area of ongoing clinical need.

    Target Audience:
    HCPs including: medical, including gynecologic, oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other clinicians who commonly encounter patients with advanced or recurrent endometrial cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: August 25, 2023
    • Expiration of CME credit: August 25, 2024
  • FREE

    ScientiaCME Targeting chronic lymphocytic leukemia (CLL): Approaches to care at different stages of the disease – Updates from ASCO 2023

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Chronic lymphocytic leukemia (CLL) is a diverse group of hematologic cancers in which B-cells accumulate in the blood, bone marrow, and lymphatic tissue, constituting as absolute lymphocytosis of mature-appearing lymphocytes with an appropriate immunophenotype. Elderly patients comprise the vast majority of those diagnosed with CLL with a median patient age of 71 years. Men have close to twice the risk of women of developing CLL, and there are over 20,000 cases per year, with an annual mortality rate in excess of 4,400.

    Target Audience:
    HCPs including: Medical oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other healthcare professionals who commonly encounter patients with CLL.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 24, 2023
    • Expiration of CME credit: July 24, 2024
  • FREE

    ScientiaCME Treating advanced-stage gastric and gastroesophageal junction cancers: updates from ASCO 2023

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Staging of GC & GEJC depends on the tumor’s histopathology, location, and degree of spread, and 36% of patients in the U.S. are diagnosed in the advanced stages of the disease because the signs and symptoms are often initially clinically silent for most of the disease course, and missed opportunities for identification are not uncommon. The prognosis of GC & GEJC is poor: the 5-year overall survival (OS) rate of GC is 32%, with the five-year OS rate of patients with advanced disease is six percent.

    Target Audience:
    HCPs including: Medical oncologists; physicians assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 27, 2023
    • Expiration of CME credit: July 27, 2024
  • FREE

    ScientiaCME Melanoma – updates from the European Society for Medical Oncology (ESMO) 2023

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Melanoma is a tumor of the melanocytes primarily occurring in the skin. The fifth most common cancer in the U.S., it occurs in over 970,000 people annually and is attributable to over 7,900 deaths each year. The five-year survival rate from diagnosis overall is 80% to 99% for patients with early stages of the disease, depending on tumor thickness. However, in patients in whom the disease that has spread to adjacent lymph nodes or tissues, the five-year survival drops to 71%, and for those with distant metastases (five percent of cases are diagnosed at this stage), the five-year survival is 32%, representing an area of ongoing clinical need.

    Target Audience:
    HCPs including: medical oncologists and dermatologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with malignant melanoma.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: December 06, 2023
    • Expiration of CME credit: December 06, 2024
  • FREE

    Novel and practical approaches to the prevention of neutropenia associated with myelosuppressive chemotherapy

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Neutropenia, a decrease in the number of a type of white blood cell (WBC) in the body, is a common complication in patients undergoing myelosuppressive chemotherapy that can result in serious, life-threatening infections. Febrile neutropenia (FN), or neutropenia accompanied by a fever, poses an even greater risk to patients and the frequent treatment complication results in over 100,000 hospitalizations in the U.S. each year. Neutropenia can manifest up to twelve days following treatment with a chemotherapy agent and FN occurs in about eight per 1,000 patients receiving chemotherapy. Fever is defined as a single oral temperature of 38.3+ °C or 38.0+ °C over the course of an hour, with neutropenia defined as less than 500 neutrophils/mcL or less than 1000 with a predicted decline to less 500 over the following 48 hours. Development of FN may lead to hospitalization with costs estimated at approximately $15,000 per visit, and it may also complicate care by reducing chemotherapy relative dose intensity (RDI) and possibly compromise treatment efficacy and lower survival rates.

    Target Audience:

    Oncologists and hematologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and other HCPs with an interest in or who clinically encounter patients with FN or at risk of developing it.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/02/2022
    • Expiration of CME credit: 06/02/2024
  • FREE

    Preventing and mitigating skeletal-related events in breast cancer

    Each year, more than 290,000 cases of breast cancer are diagnosed, making it the leading cause of cancer among females in the United States. Although earlier screening and more effective treatment options have improved outcomes among people with breast cancer, more than 43,000 people die from this type of cancer each year. Throughout the course of breast cancer management, bone health remains an important consideration. In early breast cancer, chemotherapy-induced ovarian failure and endocrine therapy can contribute to BMD loss and subsequent osteoporosis and fracture. In advanced breast cancer, about 70% of all patients will experience bone metastases, placing patients at risk for SREs. In fact, breast cancer is associated with the highest risk of SREs among all tumor types.

    Maintaining bone health in patients with breast cancer requires routine monitoring and proactive management to minimize the risk of BMD loss, osteoporosis, and SREs. Guidelines therefore recommend that patients with non-metastatic breast cancer initiating aromatase inhibitors or other treatment that causes bone loss undergo dual-energy X-ray absorptiometry (DXA) scans to assess baseline BMD. Furthermore, patients at risk for osteoporosis should receive regular follow-up DXA scans to monitor for BMD loss. This represents an opportunity for ongoing education about the need for monitoring to ensure maintenance of optimal bone health.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/27/2022
    • Expiration of CME credit: 10/27/2024